Q1 EPS Estimates for Krystal Biotech Cut by William Blair

Krystal Biotech, Inc. (NASDAQ:KRYS) – Stock analysts at William Blair dropped their Q1 2025 earnings per share estimates for shares of Krystal Biotech in a research note issued on Wednesday, April 2nd. William Blair analyst S. Corwin now forecasts that the company will earn $1.31 per share for the quarter, down from their previous estimate of $1.47. The consensus estimate for Krystal Biotech’s current full-year earnings is $6.14 per share. William Blair also issued estimates for Krystal Biotech’s Q2 2025 earnings at $1.47 EPS, Q4 2025 earnings at $2.03 EPS, FY2025 earnings at $6.65 EPS, Q1 2026 earnings at $1.60 EPS, Q2 2026 earnings at $1.94 EPS and FY2026 earnings at $9.03 EPS.

KRYS has been the subject of a number of other reports. HC Wainwright reiterated a “buy” rating and set a $221.00 target price on shares of Krystal Biotech in a research note on Friday, February 28th. Cantor Fitzgerald reiterated an “overweight” rating and set a $215.00 price objective on shares of Krystal Biotech in a research report on Thursday, February 20th. Jefferies Financial Group initiated coverage on Krystal Biotech in a research report on Wednesday, March 5th. They issued a “buy” rating and a $245.00 target price on the stock. Citigroup upped their price target on shares of Krystal Biotech from $206.00 to $215.00 and gave the company a “neutral” rating in a research report on Thursday, February 20th. Finally, Chardan Capital raised their price objective on shares of Krystal Biotech from $212.00 to $218.00 and gave the stock a “buy” rating in a report on Thursday, February 20th. One analyst has rated the stock with a hold rating, six have assigned a buy rating and one has given a strong buy rating to the company. According to data from MarketBeat.com, the stock currently has a consensus rating of “Buy” and an average target price of $220.00.

Krystal Biotech Stock Down 3.8 %

Shares of Krystal Biotech stock opened at $171.30 on Monday. Krystal Biotech has a twelve month low of $141.72 and a twelve month high of $219.34. The company’s 50 day moving average is $173.27 and its 200 day moving average is $173.00. The company has a market cap of $4.93 billion, a price-to-earnings ratio of 57.29 and a beta of 0.75.

Krystal Biotech (NASDAQ:KRYS) last released its quarterly earnings data on Monday, February 24th. The company reported $1.52 EPS for the quarter, beating the consensus estimate of $1.29 by $0.23. Krystal Biotech had a return on equity of 11.41% and a net margin of 30.69%. The company had revenue of $91.10 million for the quarter, compared to analysts’ expectations of $91.35 million. During the same period last year, the firm posted $0.30 earnings per share. Krystal Biotech’s revenue was up 116.4% compared to the same quarter last year.

Institutional Inflows and Outflows

Several hedge funds and other institutional investors have recently added to or reduced their stakes in KRYS. Wilmington Savings Fund Society FSB purchased a new position in shares of Krystal Biotech in the third quarter worth $40,000. GF Fund Management CO. LTD. bought a new stake in Krystal Biotech in the 4th quarter valued at $95,000. Covestor Ltd lifted its stake in Krystal Biotech by 972.7% in the 4th quarter. Covestor Ltd now owns 708 shares of the company’s stock worth $111,000 after purchasing an additional 642 shares in the last quarter. Avanza Fonder AB bought a new position in shares of Krystal Biotech during the 4th quarter valued at about $119,000. Finally, KBC Group NV grew its position in shares of Krystal Biotech by 46.3% during the fourth quarter. KBC Group NV now owns 939 shares of the company’s stock valued at $147,000 after purchasing an additional 297 shares in the last quarter. 86.29% of the stock is currently owned by institutional investors.

Insider Buying and Selling

In other news, CAO Kathryn Romano sold 750 shares of the company’s stock in a transaction dated Thursday, February 27th. The stock was sold at an average price of $175.22, for a total value of $131,415.00. Following the completion of the transaction, the chief accounting officer now owns 12,604 shares of the company’s stock, valued at $2,208,472.88. This represents a 5.62 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is available at this hyperlink. Also, insider Suma Krishnan sold 25,000 shares of the stock in a transaction dated Thursday, March 13th. The stock was sold at an average price of $177.79, for a total value of $4,444,750.00. Following the sale, the insider now owns 1,463,711 shares of the company’s stock, valued at $260,233,178.69. This represents a 1.68 % decrease in their position. The disclosure for this sale can be found here. 14.10% of the stock is currently owned by insiders.

Krystal Biotech Company Profile

Krystal Biotech, Inc, a commercial-stage biotechnology company, discovers, develops, and commercializes genetic medicines for patients with rare diseases in the United States. It commercializes VYJUVEK (beremagene geperpavec-svdt, or B-VEC) for the treatment of dystrophic epidermolysis bullosa (DEB).